Investigation of Milk Peptides on Postprandial Blood Glucose Profile

Inclusion Criteria: * Male and female subjects with prediabetic HbA1c values between 5.7% - 6.4% and/or Fasting blood glucose ≥ 5.6 mmol/l (≥ 100 mg/dl) und \< 7.0 mmol/l (\< 125 mg/dl) (in venous plasma) * Age: 30-70 years * Body mass index 19-35 kg/m2 * Non-smoker * Caucasian * Availability and presence in the study unit for approx. 3.5 hours/ week for 3 times in a row with approx. 1 week of washout in between. * Signed informed consent form * No changes in food habits or physical activity 3 months prior to screening and during the study Exclusion Criteria: * Presence of disease or drug(s) influencing digestion and absorption of nutrients or bowel habits * Intake of medications known to affect glucose tolerance, e.g., diabetic medication, steroids, protease inhibitors or antipsychotics * Diagnosed Typ 2-Diabetics with medical treatment * Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the investigator's opinion would impact patient safety * Severe liver, renal or cardiac disease * Acute gastrointestinal diseases including diarrhea and/or vomiting within the last 2 weeks * Known inflammatory and malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon-cancer, rectum cancer, pancreatitis) * Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs * Major medical or surgical event requiring hospitalization within the previous 3 months * Intake of antibiotics within 4 weeks before the test days * Known alcohol abuse or drug abuse * Pregnant or breast feeding women * Known or suspected allergy to any component of the investigational product(s) (e.g. milk protein) * Known HIV-infection * Known acute or chronic hepatitis B and C infection * Blood donation within 4 weeks prior to visit 1 or during the study * Subject unable to co-operate adequately * Participation in a clinical study with an investigational product within one month before start of study